Compound Database

Every half-life on StackItSmart comes from a peer-reviewed pharmacokinetic study — a clinical trial, a labeled package insert, or a published PK paper. The citation is surfaced on each compound page under "Citations." Where community reports disagree with the clinical value, the page flags the discrepancy rather than averaging them.

The lower bound of any dose range is the safer starting point. Ranges reflect published clinical dosing (FDA-labelled indication where applicable) and community-reported on-cycle usage. StackItSmart separates the two — the compound page shows both "Clinical (FDA-labelled)" and "On-cycle (community-reported)" when they differ. Start at the low end; titrate based on bloodwork, not bro-science.

Suppression is scored 0–10 relative to HPTA shutdown severity. The Cycle Builder aggregates per-compound scores into a stack total with graduated thresholds: ≤6 conservative, ≤10 moderate, ≤12 aggressive. Above 12, StackItSmart blocks the protocol as unsafe. All compounds suppressing ≥5 require post-cycle therapy.

17α-alkylated compounds (orals like anavar, dianabol, winstrol, anadrol) are modified to survive first-pass liver metabolism — which makes them hepatotoxic. StackItSmart caps 17αα cycles at 6 weeks and prohibits dual-17αα stacking. The flag appears on any oral steroid where this restriction applies.

The 123 compounds here cover the most-asked-about PEDs in the harm-reduction literature — all commonly-used anabolic steroids, SARMs, peptides, aromatase inhibitors, SERMs, HCG, and organ-support agents. New compounds are added when they are routinely cycled and have enough published PK data to cite. Gaps are intentional: if there is no peer-reviewed half-life, the compound does not ship.